Trial reportBlood2012
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
Trial report in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Trial of CC-4047 Plus Dexamethasone in Patients With Relapsed of Refractory Multiple Myeloma or Amyloidosis
Frontline Thalidomide for Amyloidosis Involving Myocardium: Investigation of Organ Reversing Capacity of Lenalidomide
Who cites it
53 citing papers in PubMed.
- Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study.Blood cancer journal · 2021Trial
- Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.International journal of hematology · 2017Trial
- Management of relapsed/refractory AL amyloidosis.Blood advances · 2026Review
- Review
- Amyloid Light Chain Proteins in Cardiovascular Disease: Pathogenesis and Emerging Therapies for Cardiac Amyloidosis.Pharmaceutical research · 2025Review
- BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis.Current oncology (Toronto, Ont.) · 2025Review
- AL Amyloidosis: Current Treatment and Outcomes.Advances in hematology · 2025Review
- Options for Rescue Treatment of Patients with AL Amyloidosis Exposed to Upfront Daratumumab.Current oncology reports · 2024Review
- Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis.Blood cancer journal · 2023Article
- Clinical characteristics and prognosis of a Chinese cohort with systemic light chain amyloidosis: a single-center study.International journal of hematology · 2023Article
- Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Targeted treatments of AL and ATTR amyloidosis.Heart failure reviews · 2022Review
- Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.Blood cancer journal · 2022Article
- AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies:JACC. CardioOncology · 2021Review
- Current Updates on the Management of AL Amyloidosis.Journal of hematology · 2021Review
- Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management.Current hematologic malignancy reports · 2021Review
- Comprehensive Review of AL amyloidosis: some practical recommendations.Blood cancer journal · 2021Review
- Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.Blood cancer journal · 2021Review
- Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.Circulation research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Immunoglobulin light-chain (AL) amyloidosis is a rare, incurable plasma cell disorder. Its therapy has benefited immensely from the expanding drug armamentarium available for multiple myeloma. Pomalidomide in combination with weekly dexamethasone (Pom/dex) is active among patients with relapsed myeloma. In the present study, we explored the Pom/dex combination in patients with previously treated AL. Patients were eligible for this prospective phase 2 trial if they had had at least one prior regimen and if they had reasonably preserved organ function. Patients were treated with oral Pom/dex. Thirty-three patients were enrolled. The median age was 66 years. Median time from diagnosis to on-study was 37 months. Eighty-two percent had cardiac involvement. The confirmed hematologic response rate was 48%, with a median time to response of 1.9 months. Organ improvement was documented in 5 patients. The median overall and progression-free survival rates were 28 and 14 months, respectively; the 1-year overall and progression-free survival rates were 76% and 59%, respectively. There was a discordance between the hematologic response and the N-terminal pro-brain natriuretic peptide response. The most common grade 3-5 adverse events, regardless of attribution, were neutropenia and fatigue. We conclude that pomalidomide appears to be a valuable drug covering an unmet clinical need in patients with previously treated AL. The trial is registered at www.clinicaltrials.gov as NCT00558896.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.